Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02)

The objective of this phase II single-arm study was to evaluate the efficacy and safety of pazopanib, a multi-targeted tyrosine kinase inhibitor, against vascular endothelial growth factor receptor (VEGFR)-1, -2, and -3, platelet-derived growth factor receptor-α and -β, and c-Kit, in recurrent gliob...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Iwamoto, Fabio M., Lamborn, Kathleen R., Robins, H. Ian, Mehta, Minesh P., Chang, Susan M., Butowski, Nicholas A., DeAngelis, Lisa M., Abrey, Lauren E., Zhang, Wei-Ting, Prados, Michael D., Fine, Howard A.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2010
Assuntos:
Clinical Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2940686/
https://ncbi.nlm.nih.gov/pubmed/20200024
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noq025
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados